NEWS
Find a Professional: Explore Experts Across 197 Disciplines in 221 Countries!
Just Updated: Compare Your Institution (Live Data)
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025 (Updated Today)
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
Login
Register & Pricing
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
For Students
local_fire_department
Country Reports
person
Find a Professional
Gijs Van De Wetering
Pharmerit International - Rotterdam / Netherlands
Others
AD Scientific Index ID: 5483265
Registration, Add Profile,
Premium Membership
Get Your Global Impact Certificate
Pharmerit International
Ranking &
Analysis
Job
Experiences
Education
Information
Published Books
Book Chapters
Articles
Presentations
Lessons
Projects
Co-Authors
Subject Leaders
Editorship, Referee &
Scientific Board
Patents /
Designs
Academic Grants
& Awards
Artistic
Activities
Certificate / Course
/ Trainings
Association &
Society Memberships
Contact, Office
& Social Media
person_outline
Gijs Van De Wetering's MOST POPULAR ARTICLES
1-)
A systematic and critical review of the evolving methods and applications of value of information in academia and practice Pharmacoeconomics 31, 25-48, 2013
2-)
The CareWell-primary care program: design of a cluster controlled trial and process evaluation of a complex intervention targeting community-dwelling frail elderly BMC Family Practice 13, 1-9, 2012
3-)
Time to incorporate time in cost-effectiveness analysis The European Journal of Health Economics 13, 223-226, 2012
4-)
A model to correct for short‐run inefficiencies in economic evaluations in healthcare Health economics 21 (3), 270-281, 2012
5-)
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States Journal of managed care & specialty pharmacy 27 (11), 1532-1544, 2021
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept